SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT00274105
- Locations
- 🇩🇪
Med. Hochschule Hannover, Hannover, Germany
🇩🇪Universitätsklinikum Charité, Berlin, Germany
Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 555
- Registration Number
- NCT00274053
- Locations
- 🇫🇷
CH Laennec, Creil, France
🇫🇷Hôpital Pitié Salpétrière, Paris, France
🇫🇷Hôpital Privé Antony, Antony, France
Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 123
- Registration Number
- NCT00273975
- Locations
- 🇿🇦
Boehringer Ingelheim Investigational Site, Tygerberg, South Africa
🇿🇦Groote Schuur Hospital, Cape Town, South Africa
Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10
- Registration Number
- NCT00273988
- Locations
- 🇮🇪
Department of Genito Urinary Medicine, St James' Hospital, Dublin, Ireland
A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 500
- Registration Number
- NCT00273962
- Locations
- 🇵🇭
Philippine General Hospital, Manila, Philippines
🇵🇭Amang Rodriguez Hospital, Marikina, Philippines
🇵🇭Quirino Memorial Medical Center, Quezon City, Philippines
Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 132
- Registration Number
- NCT00274092
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Danish Quality Assurance Project on Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in Outpatient Lung Clinics
- Conditions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2008-04-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1820
- Registration Number
- NCT00268866
Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients
- Conditions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 639
- Registration Number
- NCT00267943
- Locations
- 🇫🇷
ALTI, Angers, France
🇫🇷Hopital Avicenne, Bobigny, France
🇪🇸C.A.P. Ronda Cerdanya, Mataro / Barcelona, Spain
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
- Conditions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT00267917
- Locations
- 🇩🇪
Inamed Research GmbH & Co. KG, Gauting, Germany
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
- Conditions
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18113
- Registration Number
- NCT00262600
- Locations
- 🇸🇪
1160.26.1633 Sahlgrenska Sjukhuset, Göteboerg, Sweden
🇺🇸1160.26.0278 Boehringer Ingelheim Investigational Site, Bridgeport, Connecticut, United States
🇺🇸1160.26.0358 Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States